HypercholesterolemiaPhase 3NCT02304484
Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
A Phase 3 study testing Evolocumab in people with Hypercholesterolemia, run by Amgen at 126 sites in 29 countries.
Trial summary
The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Hypercholesterolemia
- What is being tested?
- Evolocumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 770 participants
- Where
- 126 sitesin 29 countries
- Study dates
- 24 Nov 2014to 9 Mar 2018
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Completed week 80 of study 20120153 (NCT01813422).
Who cannot join
- Did not complete investigational product in the 20120153 parent study
- Have an unstable medical condition, in the judgment of the investigator
- Known sensitivity to any of the products to be administered during dosing
- Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)
Trial locations and contacts
126 sites in 29 countries.
126 sites in 29 countries
United States24 sites
Research Site
Amarillo, Texas, 79106
Research Site
Bay City, Michigan, 48708
Research Site
Bethesda, Maryland, 20814
Research Site
Canton, Ohio, 44710
Research Site
Columbia, Maryland, 21044
Research Site
Columbia, Missouri, 65212
Research Site
Covington, Louisiana, 70433
Research Site
Dallas, Texas, 75216
Research Site
Duluth, Minnesota, 55805
Research Site
Fargo, North Dakota, 58122
Research Site
Huntsville, Alabama, 35801
Research Site
Jacksonville, Florida, 32216
Research Site
Lexington, Kentucky, 40536
Research Site
Long Beach, California, 90822
Research Site
Midland, Michigan, 48670
Research Site
Mobile, Alabama, 36608
Research Site
Munster, Indiana, 46321
Research Site
Oak Ridge, Tennessee, 37830
Research Site
Ridgewood, New Jersey, 07450
Research Site
Saint Cloud, Minnesota, 56303
Research Site
San Diego, California, 92161
Research Site
Toledo, Ohio, 43614
Research Site
Torrance, California, 90502
Research Site
Wichita Falls, Texas, 76301
Canada11 sites
Research Site
Calgary, Alberta, T2N 4Z6
Research Site
Halifax, Nova Scotia, B3H 3A7
Research Site
Laval, Quebec, H7M 3L9
Research Site
London, Ontario, N6A 5A5
Research Site
Montreal, Quebec, H1T 2M4
Research Site
Québec, Quebec, G1V 4G5
Research Site
St. John's, Newfoundland and Labrador, A1B 3V6
Research Site
Toronto, Ontario, M5B 1W8
Research Site
Toronto, Ontario, M5G 2C4
Research Site
Victoria, British Columbia, V8R 4R2
Research Site
Winnipeg, Manitoba, R2H 2A6
Australia9 sites
Research Site
Adelaide, South Australia, 5000
Research Site
Chermside, Queensland, 4032
Research Site
Epping, Victoria, 3076
Research Site
Footscray, Victoria, 3011
Research Site
Fullarton, South Australia, 5063
Research Site
Herston, Queensland, 4029
Research Site
Liverpool, New South Wales, 2170
Research Site
Nedlands, Western Australia, 6009
Research Site
New Lambton Heights, New South Wales, 2305
Netherlands9 sites
Research Site
Alkmaar, 1815 JD
Research Site
Amsterdam, 1081 HV
Research Site
Amsterdam, 1091 AC
Research Site
Leeuwarden, 8934 AD
Research Site
Nijmegen, 6532 SZ
Research Site
Rotterdam, 3079 DZ
Research Site
Tilburg, 5042 AD
Research Site
Utrecht, 3508 GZ
Research Site
Zwolle, 8025 AB
Poland6 sites
Research Site
Chrzanów, 32-500
Research Site
Kędzierzyn-Koźle, 47-200
Research Site
Krakow, 31-202
Research Site
Krakow, 31-501
Research Site
Lodz, 90-549
Research Site
Warsaw, 04-628
Spain6 sites
Research Site
Barcelona, Catalonia, 08035
Research Site
Gijón, Principality of Asturias, 33394
Research Site
L'Hospitalet de Llobregat, Catalonia, 08907
Research Site
Madrid, 28034
Research Site
Madrid, 28046
Research Site
Málaga, Andalusia, 29010
Belgium5 sites
Research Site
Antwerp, 2020
Research Site
Edegem, 2650
Research Site
Genk, 3600
Research Site
Hasselt, 3500
Research Site
Lodelinsart, 6042
France5 sites
Research Site
Besançon, 25030
Research Site
Chambray-lès-Tours, 37170
Research Site
Marseille, 13385
Research Site
Paris, 75015
Research Site
Pessac, 33604
Hungary5 sites
Research Site
Budapest, 1023
Research Site
Budapest, 1122
Research Site
Budapest, 1134
Research Site
Debrecen, 4032
Research Site
Szeged, 6725
Argentina4 sites
Research Site
Córdoba, Córdoba Province, X5016KEH
Research Site
Córdoba, X5003DCE
Research Site
Córdoba, X5021FPI
Research Site
La Plata, Buenos Aires, B1906EHD
Czechia4 sites
Research Site
Brno, 625 00
Research Site
Hradec Králové, 500 05
Research Site
Prague, 128 08
Research Site
Zlín, 762 75
Italy4 sites
Research Site
Novara, 28100
Research Site
Rozzano MI, 20089
Research Site
Sesto San Giovanni (MI), 20099
Research Site
Torino, 10154
Mexico4 sites
Research Site
Aguascalientes, 20230
Research Site
Culiacán, Sinaloa, 80230
Research Site
Guadalajara, Jalisco, 44670
Research Site
San Luis Potosí City, San Luis Potosí, 78240
Russia4 sites
Research Site
Kemerovo, 650002
Research Site
Moscow, 101990
Research Site
Moscow, 119991
Research Site
Moscow, 121552
South Korea4 sites
Research Site
Daejeon, 301-723
Research Site
Seongnam-si, Gyeonggi-do, 463-707
Research Site
Seoul, 130-872
Research Site
Seoul, 156-707
Greece3 sites
Research Site
Athens, 11527
Research Site
Athens, 14561
Research Site
Heraklion, 71110
South Africa3 sites
Research Site
Centurion, Gauteng, 0157
Research Site
Kuils River, Western Cape, 7580
Research Site
Sunninghill, Gauteng, 2157
Brazil2 sites
Research Site
Porto Alegre, Rio Grande do Sul, 90620-001
Research Site
São Paulo, 05403-000
Malaysia2 sites
Research Site
George Town, 10050
Research Site
Kuantan, Pahang, 25100
About this study
Official title: A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab
The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.
- Conditions
- Hypercholesterolemia
- Being tested
- Evolocumab
- Medical subject headings
- Hypercholesterolemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EvolocumabBiological
Also called AMG 145, Repatha
Administered by subcutaneous injection once a month
| Study group | Role | What they receive |
|---|---|---|
| Evolocumab | Experimental | Participants received 420 mg evolocumab once a month for up to 2 years. Receives: Biological: Evolocumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Adverse Events
The severity of each adverse event (AE) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 criteria, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe or medically significant AE, Grade 4 = Life-threatening consequences, and Grade 5 = death related to AE.
An adverse device effect was defined as any adverse event related to the use of a medical device (autoinjector/pen or automated mini doser [AMD]), including but not limited to, AEs resulting from insufficient or inadequate Instructions for Use, AEs resulting from any malfunction of the device, or AEs resulting from use error or from intentional misuse of the device.
Measured: From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks.
Secondary outcomes (1)
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Measured: Baseline (of study 20120153) and weeks 0, 4, 12, 24, 36, 48, 52, 76, and 104 of study 20140128
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2014 (estimated)
- Study start24 Nov 2014
- Primary completion9 Mar 2018
- Study completion9 Mar 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for HypercholesterolemiaStudies of the same condition, open and under way.
- More trials run by AmgenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 770 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amgen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MD, Study director, Amgen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02304484
- Sponsor's protocol ID
- 20140128
- Other IDs
- 2014-001524-30, 2014
- Status last verified
- Feb 2019
- First submitted
- 7 Oct 2014
- Last updated
- 19 Mar 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab
- ClinicalTrials.gov ID
- NCT02304484
- Acronym / sponsor ID
- 20140128
- Conditions
- Hypercholesterolemia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 770 participants (actual)
- Lead sponsor
- AmgenIndustry (pharma, biotech, devices)
- Study start
- 24 Nov 2014 (actual)
- Primary completion
- 9 Mar 2018 (actual)
- Study completion
- 9 Mar 2018 (actual)
- First posted
- 2 Dec 2014 (estimated)
- Results
- Posted 19 Mar 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Evolocumab | Experimental | Biological: EvolocumabParticipants received 420 mg evolocumab once a month for up to 2 years. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Completed week 80 of study 20120153 (NCT01813422).
Key exclusion criteria (4 listed)
- Did not complete investigational product in the 20120153 parent study
- Have an unstable medical condition, in the judgment of the investigator
- Known sensitivity to any of the products to be administered during dosing
- Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EvolocumabAlso: AMG 145, RepathaAdministered by subcutaneous injection once a month | Biological | Evolocumab |
Primary outcome
Number of Participants With Adverse Events
Time frame: From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks.
The severity of each adverse event (AE) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 criteria, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe or medically significant AE, Grade 4 = Life-threatening consequences, and Grade 5 = death related to AE. An adverse device effect was defined as any adverse event related to the use of a medical device (autoinjector/pen or automated mini doser [AMD]), including but not limited to, AEs resulting from insufficient or inadequate Instructions for Use, AEs resulting from any malfunction of the device, or AEs resulting from use error or from intentional misuse of the device.
1 secondary outcome
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time frame: Baseline (of study 20120153) and weeks 0, 4, 12, 24, 36, 48, 52, 76, and 104 of study 20140128
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- AmgenTrials clinical trials websiteLink provided by the sponsor.
Related trials for Hypercholesterolemia
Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Active, not recruitingObservational study
Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)
Familial Hypercholesterolaemia
Not yet recruiting
Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3
Familial Hypercholesterolemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MD study director
Amgen
126 sites in 29 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Evolocumab in people with Hypercholesterolemia, run by Amgen at 126 sites in 29 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 126 sites in United States, Canada, Australia, Netherlands, Poland and 24 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Mar 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Adverse Events (time frame: From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019.